The U.S. Food and Drug Administration announced the Global Reliance Disclosure Program on Wednesday, a new initiative designed to accelerate patient access to medicines by sharing detailed regulatory assessments with international health authorities. The program allows foreign regulators to rely on the FDA’s rigorous scientific reviews, reducing the need for duplicative evaluations that often delay drug availability in other countries.
Sharing FDA Assessments Globally
Under the new framework, the FDA will provide companies with minimally redacted approval packages. These documents include the agency’s detailed scientific and regulatory assessments. Companies can then share these materials with regulatory authorities outside the United States. This process empowers foreign agencies to make decisions based on the FDA’s science-based review rather than conducting their own time-consuming product evaluations.
Grace Graham, the FDA Deputy Commissioner for Policy, Legislation, and International Affairs, stated that the program reflects an interest in advancing global health. She noted that making it easier for applicants to use FDA assessments facilitates faster access for patients everywhere. The initiative aims to maintain the sovereignty of foreign regulatory bodies while leveraging the FDA’s established standards.
Launch and Expansion Timeline
The program officially launched on October 30. Its initial phase focuses on tentative approvals under the President’s Emergency Plan for AIDS Relief, specifically for lenacapavir, a drug used for HIV prevention and treatment. This starting point aligns with the program’s goal to support life-saving missions in vulnerable populations. Currently, the program excludes tentatively approved abbreviated new drug application products.
The FDA plans to significantly expand the program in January 2027. At that time, it will become available for all novel drug and biologic applications, including New Molecular Entity New Drug Applications and 351(a) Biologics License Applications. This expansion is expected to dramatically broaden the program’s reach and impact on global health security.
Additionally, the agency intends to launch a pathway in early 2027. This new route will allow applicants to expedite their requests for minimally redacted action packages for drugs and biologics already approved and licensed in the United States. This step aims to accelerate global access to medicines that have already been found safe and effective by the FDA.
Requirements for Participation
To receive a minimally redacted application approval package, applicants must request participation within 10 calendar days of approval. They must also confirm that the package is being submitted to a foreign regulatory authority to support a marketing application. The FDA intends to provide these packages on an expedited basis for eligible requests.
Requests for other purposes will not be processed under this program. Applicants seeking documents for different reasons must submit a Freedom of Information Act request instead. Mark Abdoo, the FDA Associate Commissioner for Global Policy and Strategy, emphasized that the agency’s leadership is most effective when collaborative. He described the program as a forward-looking vision defined by a willingness to share expertise and put patients first.
The initiative addresses the persistent gap between regulatory approval in high-capacity countries and patient access in lower-resource settings. When a drug is approved by the FDA, patients in many parts of the world may wait months or years for their national health authority to complete an independent review. Limited regulatory capacity and resources often contribute to these delays.
Harmonized regulatory decisions help reduce the risk of fragmented product standards across markets. This approach ensures that high-quality therapies reach patients regardless of their location. The FDA, an agency within the U.S. Department of Health and Human Services, continues to protect public health by assuring the safety and effectiveness of human and veterinary drugs, vaccines, and medical devices.
Source: U.S. FDA

